The Biological Computing Co. just pulled off something that sounds like science fiction until you realize Primary Ventures wired $25M to make it very real.
In a world addicted to bigger GPUs and louder data centers, The Biological Computing Co. looked at silicon and said, that is cute. Alexander Ksendzovsky and Jonathan Pomeraniec, both neurosurgeon scientists, decided to build with the original processor. Neurons. Living ones. Not metaphors. Not marketing. Actual biological networks encoding images and video, decoding neural activity into representations that plug directly into state of the art AI models.
This is a San Francisco outfit, Mission Bay lab humming, formerly known as Biological Black Box. Now operating as The Biological Computing Co., and the name is not subtle. They are not optimizing chips. They are questioning the substrate. Encode real world data into living neurons. Decode the signals. Map them through modular adapters into frontier models. A new compute layer that strengthens existing AI systems instead of trying to cosplay as one.
Congratulations to Alexander Ksendzovsky and Jonathan Pomeraniec for having the nerve and the science to do what most people only debate on panels. Building biological computing for computer vision, generative video, and AI infrastructure is not a pivot. It is a thesis.
Primary Ventures led the round, with Brian Schechter and Gaby Lorenzi backing the conviction. Scott Belsky, partner at A24 and previous chief of strategy at Adobe, sees the signal. Tim Gardner, co founder of Neuralink, understands what it means when living neuronal cultures stop being lab curiosities and start becoming infrastructure. When operators like that lean in, it is not because the deck had pretty gradients.
The business lesson is sharp. They did not pitch hype. They pitched architecture. They positioned biological computing not as rebellion against silicon, but as reinforcement for frontier models under tight energy constraints. In a market obsessed with scaling transformers, The Biological Computing Co. is scaling biology. That is how you earn a seed round that feels like a Series A in ambition.
For founders watching this, notice the pattern. Deep domain credibility. A clear technical narrative. A lab you can point to in Mission Bay. A problem framed around world models and demanding AI workloads, not buzzwords. Investors do not fund vibes at this level. They fund inevitability.
For AI teams wrestling with compute ceilings and power budgets, the message is quieter but louder at the same time. There may be another layer available. One that learns the way nature intended before we ever etched our first transistor.
